Basic Mechanisms and Cancer Therapy
Buch, Englisch, 845 Seiten, Paperback, Format (B × H): 210 mm x 279 mm, Gewicht: 2061 g
ISBN: 978-3-662-51798-7
Verlag: Springer
This book is divided into 3 parts. Part 1 summarizes the pro-angiogenic factors and anti-angiogenic molecules including their mechanism of action. Part 2 summarizes the preclinical data arising from the experimental evaluation of anti-angiogenic and pro-angiogenic compounds in cell culture and animal models. This will help to elucidate their mechanism of action in different biologic systems and cancer types. Based on this knowledge, clinicians will be able to incorporate these new drugs into the scenario of established therapies and finally improve curative approaches. Part 3 summarizes experimental and clinical studies of combined therapy with anti-angiogenic agents and highlights the challenges related to the appropriate strategies for selection of the patients, study design, and choice of proper end points for preclinical and clinical studies using these agents.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
Weitere Infos & Material
Historical Overview.- Tumor Angiogenesis: from Bench to Bedside.- Mechanisms.- Vasculogenesis and Angiogenesis in Development.- Guidance of Vascular and Neuronal Network Formation.- The Angiogenic Switch in Tumorigenesis.- Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor.- Regulation of Angiogenesis and Vascular Homeostasis Through the Angiopoietin / Tie System.- Eph Receptors and Ephrins: Role in Vascular Development and Tumor Angiogenesis.- The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression.- Platelet-derived Growth Factor: Impact on Physiological and Tumor Angiogenesis.- Hypoxia and Tumour Angiogenesis.- Hypoxia and Angiogenesis in Glioblastomas.- Endogenous Inhibitors of Angiogenesis.- Thrombospondins and Angiogenesis.- Molecular and Cellular Aspects of Heparanase.- Vessel Maturation and Perivascular Cells.- Adhesion Molecules in the Vascular Cell Cross-Talk.- Homing and Differentiation of Endothelial Progenitor Cells.- Molecular Players in Lymphangiogenesis.- The Relationship Between Tumors and the Lymphatics: Consequences for Metastasis.- Inflammation and Angiogenesis: Innate Immune Cells as Modulators of Tumor Vascularization.- Arteriovenous Malformation in Mice and Men.- Animal Models and Preclinical Anti-Angiogenic Studies.- Vascular Endothelial Growth Factor Antibodies for Anti-Angiogenic Therapy.- Vascular Endothelial Growth Factor.- Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy.- Angiopoietin-2 Antagonists for Anti-Angiogenic Therapy.- Anti-Angiogenic Therapy with Thrombospondins.- The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer.- Vascular Tumor Targeting.- Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis.- Imaging of Tumor Angiogenesis and Antiangiogenesis.- Visualization of Microcirculation and Anti-Angiogenic Tumor Therapy.- Cellular Actions of Angiogenesis Inhibitors on Blood Vessels.- Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment.- Metronomic Antiangiogenic Chemotherapy: Questions and Answers.- Anti-Angiogenic Tumor Therapy in Clinical Studies.- The Development of Avastin.- Clinical Development of Sorafenib (BAY 43–9006) VEGFR and RAF Inhibitor.- Clinical Development of the VEGFR Signalling Inhibitor AZD2171.- Clinical Development of Sunitinib Malate.- The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy.- Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies.- Vandetanib (ZACTIMA™; ZD6474): Preclinical and Clinical Development.- Integrins: Targets for Anti-Angiogenic Therapy.- Thalidomide in Multiple Myeloma.- Surrogate Markers of Angiogenesis.- Vascular Disrupting Agents in Cancer Therapy.
